Key terms
About CERT
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CERT news
May 10
1:52am ET
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
May 10
1:39am ET
Certara Analyst Maintains Hold Rating Amid Mixed Financial Performance and Strategic Developments
Apr 16
8:05am ET
Certara announces the launch of Certara Cloud
Apr 04
4:23am ET
Certara initiated with a Market Perform at JMP Securities
Apr 04
12:35am ET
Maintaining Hold Rating for Certara Amid Balanced Financials and Industry Headwinds
Mar 01
6:56am ET
Certara price target raised to $20 from $17 at UBS
Mar 01
2:55am ET
Barclays Issues a Hold Rating on Certara (CERT)
Feb 29
4:45pm ET
Certara sees FY24 EPS 41c-46c, consensus 48c
Feb 29
4:42pm ET
Certara reports Q4 EPS 9c, consensus 11c
Feb 26
6:25am ET
Certara initiated with a Market Perform at Leerink
No recent press releases are available for CERT
CERT Financials
Key terms
Ad Feedback
CERT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CERT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
